Pluri (PLUR) AI Stock Analysis

• Market Cap: $38.18M
• Dividend Yield: N/A
• Average Volume (3M): 23.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 89.92%
• EPS Growth: 21.39%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -3.68
• Shares Outstanding: 7,797,680
• 10 Day Avg. Volume: 55,960
• 30 Day Avg. Volume: 23,392
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 133.85
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pluri's overall score is impacted primarily by its significant financial challenges and valuation issues. The company's strategic board appointment is a positive step, but it does not outweigh the risks posed by high leverage, negative cash flow, and ongoing operational losses.

Pluri Business Overview & Revenue Model

Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

How the Company Makes Money

null

Pluri Financial Statement Overview

Summary

Pluri faces significant financial challenges across its income statement, balance sheet, and cash flow. The company struggles with profitability, high leverage, and negative cash flow, posing substantial risks to financial stability.

Income Statement

Pluri's income statement reveals persistent challenges, characterized by negative EBIT and EBITDA margins, indicating substantial operational losses. The gross profit margin is exceptionally high in TTM (Trailing-Twelve-Months), but this is offset by significant net losses, resulting in a negative net profit margin. Revenue growth is inconsistent, with occasional increases, but overall revenue remains minimal compared to industry standards.

Balance Sheet

The balance sheet highlights financial instability, with a negative stockholders' equity indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, suggesting high leverage and financial risk. The company's equity ratio is unfavorably negative, indicative of a weak financial foundation.

Cash Flow

Cash flow statements show negative free cash flow and operating cash flow, reflecting cash outflows exceeding inflows. The free cash flow to net income ratio is unfavorable, and the operating cash flow to net income ratio is also negative, indicating cash flow issues. Despite efforts to raise financing, the cash flow situation remains challenging.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
326.00K	287.00K	234.00K	0.00	23.00K
	Gross Profit
322.00K	278.00K	-41.36M	-50.62M	-1.55M
	EBIT
-22.16M	-27.25M	-41.59M	-50.62M	-29.48M
	EBITDA
-20.23M	-27.68M	-39.43M	-48.42M	-27.39M
	Net Income Common Stockholders
-20.89M	-28.32M	-41.02M	-49.94M	-29.35M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
30.24M	40.17M	55.02M	64.95M	45.78M
	Total Assets
39.53M	50.80M	68.06M	93.54M	65.53M
	Total Debt
29.61M	29.91M	28.80M	24.58M	1.58M
	Net Debt
22.83M	24.55M	19.03M	-6.66M	-6.68M
	Total Liabilities
34.11M	35.50M	35.88M	36.39M	9.43M
	Stockholders Equity
96.00K	13.36M	30.04M	57.15M	56.10M
Cash Flow		Free Cash Flow
-18.34M	-23.12M	-36.78M	-31.28M	-26.64M
	Operating Cash Flow
-18.02M	-22.86M	-36.50M	-30.91M	-26.37M
	Investing Cash Flow
10.58M	9.70M	11.78M	-7.26M	-30.46M
	Financing Cash Flow
8.84M	8.02M	7.50M	61.40M	60.87M

Pluri Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Neutral. The current price of 4.9 is above the 20-day moving average (MA) of 4.43, above the 50-day MA of 4.48, and above the 200-day MA of 4.89, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 51.93 is Neutral, neither overbought nor oversold. The STOCH value of 32.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLUR.

Pluri Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
DARE	46 Neutral	$26.37M	―	597.53%	―	88.13%	92.45%
GDTC	41 Neutral	$26.77M	―	-24.97%	―	―	38.80%
PLUR	40 Underperform	$38.18M	―	-1205.58%	―	89.92%	21.39%
TPST	39 Underperform	$24.11M	―	-182.35%	―	―	-220.54%
CLNN	39 Underperform	$26.69M	―	-1738.36%	―	-47.71%	-244.00%
NRSN	30 Underperform	$25.43M	―	-2880.11%	―	―	31.09%

Pluri Corporate Events

Pluri Strengthens Leadership Amid Strategic Board Appointment

Pluri Inc. announced the appointment of Mr. Weinstein as a director of the Board, effective immediately upon the closing of a recent offering. Mr. Weinstein has extensive experience in the pharmaceutical, biotechnology, and sustainable technology sectors, and holds positions in several ventures and companies. This appointment is part of a broader strategic move associated with the company’s recent securities offering, which also involves a Securities Purchase Agreement. The move aims to strengthen Pluri’s leadership with Mr. Weinstein’s expertise, potentially impacting the company’s market positioning and operational strategy.